C12N 2710/16643
Viral genome or elements thereof as genetic vector
Official title: viral genome or elements thereof as genetic vector
C12N2710/16643 (Viral genome or elements thereof as genetic vector) appears on 283 US grants and 416 published applications in this corpus.
Search patents in C12N- Granted patents
- 283
- Published applications
- 416
- Assignees
- 170
- Inventors
- 542
- Latest grant
- 21 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 2 | 0 |
| 1995 | 2 | 0 |
| 1996 | 2 | 0 |
| 1997 | 6 | 0 |
| 1998 | 14 | 0 |
| 1999 | 6 | 0 |
| 2000 | 12 | 0 |
| 2001 | 10 | 8 |
| 2002 | 9 | 17 |
| 2003 | 9 | 13 |
| 2004 | 11 | 20 |
| 2005 | 6 | 14 |
| 2006 | 9 | 12 |
| 2007 | 7 | 17 |
| 2008 | 3 | 9 |
| 2009 | 9 | 13 |
| 2010 | 9 | 10 |
| 2011 | 5 | 14 |
| 2012 | 11 | 7 |
| 2013 | 7 | 11 |
| 2014 | 7 | 5 |
| 2015 | 7 | 12 |
| 2016 | 4 | 10 |
| 2017 | 10 | 12 |
| 2018 | 8 | 11 |
| 2019 | 11 | 17 |
| 2020 | 16 | 32 |
| 2021 | 4 | 24 |
| 2022 | 16 | 29 |
| 2023 | 7 | 29 |
| 2024 | 15 | 24 |
| 2025 | 15 | 27 |
| 2026 | 13 | 19 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Treatment using oncolytic virus21 Jul 2026US 12,685,767 B2Replimune Limited
- Poly(β-amino ester)-co-polyethylene glycol (PEG-PBAE-PEG) polymers for gene and drug delivery2 Jun 2026US 12,643,980 B2The Johns Hopkins University
- Recombinant oncolytic virus, preparation method therefor, use thereof and medicine thereof26 May 2026US 12,636,329 B2
- Oncolytic virus compositions and methods for the treatment of cancer26 May 2026US 12,637,510 B2City of Hope
- Recombinant herpes simplex virus for multiple targeting and use thereof19 May 2026US 12,629,399 B2Gencellmed Inc.
- Recombinant herpes simplex virus with il-12 expression8 Oct 2026US 2026/0308219 A1
- Use of oncolytic viruses for the treatment of cancer24 Sep 2026US 2026/0286393 A1Amgen Inc.
- Compositions and Methods for the Treatment of ATPase Disorders or Diseases of the Skin24 Sep 2026US 2026/0286394 A1Krystal Biotech, Inc.
- Viral Vectors For Treating Neurogenic Detrusor Overactivity3 Sep 2026US 2026/0258426 A1Assistance Publique-Hopitaux de Paris
- Hsv gene expression vector and bxb1 integrase-mediated recombination system for high-throughput cloning27 Aug 2026US 2026/0250643 A1Albert Einstein College of Medicine
Most cited
By later US patents
- Herpes Simplex virus as a vector100US 5,288,641 AArch Development Corporation · 1994
- Viral-mediated gene transfer system97US 5,672,344 AThe Regents of the University of Michigan · 1997
- Compositions and methods for regulating production of a precursor protein87US 11,873,505 B2Wyvern Pharmaceuticals Inc. · 2024
- Replication-competent herpes simplex virus mediates destruction of neoplastic cells76US 5,585,096 AGeorgetown University · 1996
- Recombinant herpes simplex viruses vaccines and methods75US 5,328,688 AArch Development Corporation · 1994